Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 107

1.

Remotely controlled chemomagnetic modulation of targeted neural circuits.

Rao S, Chen R, LaRocca AA, Christiansen MG, Senko AW, Shi CH, Chiang PH, Varnavides G, Xue J, Zhou Y, Park S, Ding R, Moon J, Feng G, Anikeeva P.

Nat Nanotechnol. 2019 Aug 19. doi: 10.1038/s41565-019-0521-z. [Epub ahead of print]

PMID:
31427746
2.

Molecular Characterization of Coxsackievirus B5 Isolates from Sewage, Italy 2016-2017.

Fontana S, Fiore S, Buttinelli G, Amato C, Veronesi L, Zoni R, Triassi M, Pennino F, Giammanco GM, De Grazia S, Cicala A, Siragusa A, Gamper S, Spertini S, Castiglia P, Cossu A, Germinario C, Larocca AMV, Stefanelli P.

Food Environ Virol. 2019 Jul 26. doi: 10.1007/s12560-019-09395-z. [Epub ahead of print]

PMID:
31346976
3.

Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial.

Mateos MV, Blacklock H, Schjesvold F, Oriol A, Simpson D, George A, Goldschmidt H, Larocca A, Chanan-Khan A, Sherbenou D, Avivi I, Benyamini N, Iida S, Matsumoto M, Suzuki K, Ribrag V, Usmani SZ, Jagannath S, Ocio EM, Rodriguez-Otero P, San Miguel J, Kher U, Farooqui M, Liao J, Marinello P, Lonial S; KEYNOTE-183 Investigators.

Lancet Haematol. 2019 Jul 18. pii: S2352-3026(19)30110-3. doi: 10.1016/S2352-3026(19)30110-3. [Epub ahead of print]

PMID:
31327687
4.

First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials.

Larocca A, Mina R, Offidani M, Liberati AM, Ledda A, Patriarca F, Evangelista A, Spada S, Benevolo G, Oddolo D, Innao V, Cangialosi C, Bernardini A, Musto P, Amico V, Fraticelli V, Paris L, Giuliani N, Falcone AP, Zambello R, De Paoli L, Romano A, Palumbo A, Montefusco V, Hajek R, Boccadoro M, Bringhen S.

Haematologica. 2019 Jun 27. pii: haematol.2019.220657. doi: 10.3324/haematol.2019.220657. [Epub ahead of print]

5.

Frailty in multiple myeloma: the need for harmony to prevent doing harm.

Zweegman S, Larocca A.

Lancet Haematol. 2019 Mar;6(3):e117-e118. doi: 10.1016/S2352-3026(19)30011-0. Epub 2019 Feb 6. No abstract available.

6.

Once-weekly versus twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: a pooled analysis of two phase I/II studies.

Bringhen S, Mina R, Petrucci MT, Gaidano G, Ballanti S, Musto P, Offidani M, Spada S, Benevolo G, Ponticelli E, Galieni P, Cavo M, Di Toritto TC, Di Raimondo F, Montefusco V, Palumbo A, Boccadoro M, Larocca A.

Haematologica. 2019 Aug;104(8):1640-1647. doi: 10.3324/haematol.2018.208272. Epub 2019 Feb 7.

7.

Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension.

Bringhen S, Milan A, D'Agostino M, Ferri C, Wäsch R, Gay F, Larocca A, Offidani M, Zweegman S, Terpos E, Goldschmidt H, Cavo M, Ludwig H, Driessen C, Auner HW, Caers J, Gramatzki M, Dimopoulos MA, Boccadoro M, Einsele H, Sonneveld P, Engelhardt M.

J Intern Med. 2019 Jul;286(1):63-74. doi: 10.1111/joim.12882. Epub 2019 Apr 8.

PMID:
30725503
8.

Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial.

Saltarella I, Morabito F, Giuliani N, Terragna C, Omedè P, Palumbo A, Bringhen S, De Paoli L, Martino E, Larocca A, Offidani M, Patriarca F, Nozzoli C, Guglielmelli T, Benevolo G, Callea V, Baldini L, Grasso M, Leonardi G, Rizzo M, Falcone AP, Gottardi D, Montefusco V, Musto P, Petrucci MT, Dammacco F, Boccadoro M, Vacca A, Ria R.

J Hematol Oncol. 2019 Jan 9;12(1):4. doi: 10.1186/s13045-018-0691-4.

9.

Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis.

Gambella M, Omedé P, Spada S, Muccio VE, Gilestro M, Saraci E, Grammatico S, Larocca A, Conticello C, Bernardini A, Gamberi B, Troia R, Liberati AM, Offidani M, Rocci A, Palumbo A, Cavo M, Sonneveld P, Boccadoro M, Oliva S.

Cancer. 2019 Mar 1;125(5):750-760. doi: 10.1002/cncr.31854. Epub 2018 Dec 18.

PMID:
30561775
10.

Special problems in the management of elderly patients with multiple myeloma.

Gay F, Larocca A.

Eur J Intern Med. 2018 Dec;58:64-69. doi: 10.1016/j.ejim.2018.05.027. Review.

PMID:
30527921
11.

HBV seroprevalence after 25 years of universal mass vaccination and management of non-responders to the anti-Hepatitis B vaccine: An Italian study among medical students.

Bianchi FP, Gallone MS, Gallone MF, Larocca AMV, Vimercati L, Quarto M, Tafuri S.

J Viral Hepat. 2019 Jan;26(1):136-144. doi: 10.1111/jvh.13001. Epub 2018 Oct 17.

PMID:
30199579
12.

Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis: A pooled analysis.

Bringhen S, Offidani M, Palmieri S, Pisani F, Rizzi R, Spada S, Evangelista A, Di Renzo N, Musto P, Marcatti M, Vallone R, Storti S, Bernardini A, Centurioni R, Aitini E, Palmas A, Annibali O, Angelucci E, Ferrando P, Baraldi A, Rocco S, Andriani A, Siniscalchi A, De Stefano V, Meneghini V, Palumbo A, Grammatico S, Boccadoro M, Larocca A.

Crit Rev Oncol Hematol. 2018 Oct;130:27-35. doi: 10.1016/j.critrevonc.2018.07.003. Epub 2018 Jul 18. Review.

PMID:
30196909
13.

European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when.

Caers J, Garderet L, Kortüm KM, O'Dwyer ME, van de Donk NWCJ, Binder M, Dold SM, Gay F, Corre J, Beguin Y, Ludwig H, Larocca A, Driessen C, Dimopoulos MA, Boccadoro M, Gramatzki M, Zweegman S, Einsele H, Cavo M, Goldschmidt H, Sonneveld P, Delforge M, Auner HW, Terpos E, Engelhardt M.

Haematologica. 2018 Nov;103(11):1772-1784. doi: 10.3324/haematol.2018.189159. Epub 2018 Aug 31.

14.

Cardiovascular adverse events in modern myeloma therapy - Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA).

Bringhen S, Milan A, Ferri C, Wäsch R, Gay F, Larocca A, Salvini M, Terpos E, Goldschmidt H, Cavo M, Petrucci MT, Ludwig H, Auner HW, Caers J, Gramatzki M, Boccadoro M, Einsele H, Sonneveld P, Engelhardt M; European Hematology Association, the European Myeloma Network and the Italian Society of Arterial Hypertension.

Haematologica. 2018 Sep;103(9):1422-1432. doi: 10.3324/haematol.2018.191288. Epub 2018 Jul 26. Review.

15.

Landfill siting based on optimisation, multiple decision analysis, and geographic information system analyses.

Spigolon LM, Giannotti M, Larocca AP, Russo MA, Souza NDC.

Waste Manag Res. 2018 Jul;36(7):606-615. doi: 10.1177/0734242X18773538. Epub 2018 Jun 20.

PMID:
29921168
16.

Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN).

Larocca A, Dold SM, Zweegman S, Terpos E, Wäsch R, D'Agostino M, Scheubeck S, Goldschmidt H, Gay F, Cavo M, Ludwig H, Straka C, Bringhen S, Auner HW, Caers J, Gramatzki M, Offidani M, Dimopoulos MA, Einsele H, Boccadoro M, Sonneveld P, Engelhardt M.

Leukemia. 2018 Aug;32(8):1697-1712. doi: 10.1038/s41375-018-0142-9. Epub 2018 Apr 25. Review.

17.

Gentle yet effective combination therapy with novel agents in elderly multiple myeloma patients.

Larocca A, D'Agostino M, Boccadoro M.

Br J Haematol. 2018 Jul;182(2):165-167. doi: 10.1111/bjh.15260. Epub 2018 May 6. No abstract available.

PMID:
29732537
18.

Pharmacokinetic drug evaluation of ixazomib citrate for the treatment of multiple myeloma.

Salvini M, Troia R, Giudice D, Pautasso C, Boccadoro M, Larocca A.

Expert Opin Drug Metab Toxicol. 2018 Jan;14(1):91-99. doi: 10.1080/17425255.2018.1417388. Epub 2017 Dec 19. Review.

19.

Emerging drugs and combinations to treat multiple myeloma.

Larocca A, Mina R, Gay F, Bringhen S, Boccadoro M.

Oncotarget. 2017 Jul 15;8(36):60656-60672. doi: 10.18632/oncotarget.19269. eCollection 2017 Sep 1. Review.

20.

Erratum to: lack of immunity against rubella among Italian young adults.

Gallone MS, Gallone MF, Larocca AMV, Germinario C, Tafuri S.

BMC Infect Dis. 2017 Sep 19;17(1):630. doi: 10.1186/s12879-017-2724-y. No abstract available.

21.

"To stent or not to stent?": immediate emergency surgery with laparoscopic radical colectomy with CME and primary anastomosis is feasible for obstructing left colon carcinoma.

Di Saverio S, Birindelli A, Segalini E, Novello M, Larocca A, Ferrara F, Binda GA, Bassi M.

Surg Endosc. 2018 Apr;32(4):2151-2155. doi: 10.1007/s00464-017-5763-y. Epub 2017 Aug 8.

PMID:
28791424
22.

Elderly patients with multiple myeloma: towards a frailty approach?

Zweegman S, Engelhardt M, Larocca A; EHA SWG on ‘Aging and Hematology’.

Curr Opin Oncol. 2017 Sep;29(5):315-321. doi: 10.1097/CCO.0000000000000395. Review.

23.

Melphalan hydrochloride for the treatment of multiple myeloma.

Esma F, Salvini M, Troia R, Boccadoro M, Larocca A, Pautasso C.

Expert Opin Pharmacother. 2017 Aug;18(11):1127-1136. doi: 10.1080/14656566.2017.1349102. Epub 2017 Jul 10. Review.

24.

Second primary malignancies in multiple myeloma: an overview and IMWG consensus.

Musto P, Anderson KC, Attal M, Richardson PG, Badros A, Hou J, Comenzo R, Du J, Durie BGM, San Miguel J, Einsele H, Chen WM, Garderet L, Pietrantuono G, Hillengass J, Kyle RA, Moreau P, Lahuerta JJ, Landgren O, Ludwig H, Larocca A, Mahindra A, Cavo M, Mazumder A, McCarthy PL, Nouel A, Rajkumar SV, Reiman A, Riva E, Sezer O, Terpos E, Turesson I, Usmani S, Weiss BM, Palumbo A; International Myeloma Working Group.

Ann Oncol. 2018 Apr 1;29(4):1074. doi: 10.1093/annonc/mdx160. No abstract available.

PMID:
28541409
25.

How is patient care for multiple myeloma advancing?

Genadieva Stavric S, Bonello F, Bringhen S, Boccadoro M, Larocca A.

Expert Rev Hematol. 2017 Jun;10(6):551-561. doi: 10.1080/17474086.2017.1326814. Epub 2017 May 19. Review.

PMID:
28504554
26.

Novel investigational drugs active as single agents in multiple myeloma.

D'Agostino M, Salvini M, Palumbo A, Larocca A, Gay F.

Expert Opin Investig Drugs. 2017 Jun;26(6):699-711. doi: 10.1080/13543784.2017.1324571. Epub 2017 May 8. Review.

PMID:
28448171
27.

Lack of immunity against rubella among Italian young adults.

Gallone MS, Gallone MF, Larocca AMV, Germinario C, Tafuri S.

BMC Infect Dis. 2017 Mar 7;17(1):199. doi: 10.1186/s12879-017-2295-y. Erratum in: BMC Infect Dis. 2017 Sep 19;17 (1):630.

28.

Fatty Acids in Membranes as Homeostatic, Metabolic and Nutritional Biomarkers: Recent Advancements in Analytics and Diagnostics.

Ferreri C, Masi A, Sansone A, Giacometti G, Larocca AV, Menounou G, Scanferlato R, Tortorella S, Rota D, Conti M, Deplano S, Louka M, Maranini AR, Salati A, Sunda V, Chatgilialoglu C.

Diagnostics (Basel). 2016 Dec 22;7(1). pii: E1. doi: 10.3390/diagnostics7010001. Review.

29.

Lenalidomide and low-dose dexamethasone (Rd) versus bortezomib, melphalan, prednisone (VMP) in elderly newly diagnosed multiple myeloma patients: A comparison of two prospective trials.

Gentile M, Magarotto V, Offidani M, Musto P, Bringhen S, Teresa Petrucci M, Gay F, Larocca A, Uccello G, Petrungaro A, Vigna E, Greco R, Grazia Recchia A, Tripepi G, Ria R, Di Raimondo F, Palumbo A, Morabito F.

Am J Hematol. 2017 Mar;92(3):244-250. doi: 10.1002/ajh.24621. Epub 2017 Jan 23.

30.

Management of adverse events induced by next-generation immunomodulatory drug and proteasome inhibitors in multiple myeloma.

Salvini M, Bonello F, Boccadoro M, Larocca A.

Expert Rev Anticancer Ther. 2017 Jan;17(1):75-87. Epub 2016 Dec 9. Review.

PMID:
27894203
31.

Salvage therapy in first relapse: a retrospective study in a large patient population with multiple myeloma.

Offidani M, Corvatta L, Bringhen S, Gentili S, Troia R, Maracci L, Larocca A, Gay F, Leoni P, Boccadoro M.

Eur J Haematol. 2017 Mar;98(3):289-295. doi: 10.1111/ejh.12834. Epub 2017 Jan 5.

PMID:
27893171
32.

Second primary malignancies in multiple myeloma: an overview and IMWG consensus.

Musto P, Anderson KC, Attal M, Richardson PG, Badros A, Hou J, Comenzo R, Du J, Durie BGM, San Miguel J, Einsele H, Chen WM, Garderet L, Pietrantuono G, Hillengass J, Kyle RA, Moreau P, Lahuerta JJ, Landgren O, Ludwig H, Larocca A, Mahindra A, Cavo M, Mazumder A, McCarthy PL, Nouel A, Rajkumar SV, Reiman A, Riva E, Sezer O, Terpos E, Turesson I, Usmani S, Weiss BM, Palumbo A; International Myeloma Working Group.

Ann Oncol. 2017 Feb 1;28(2):228-245. doi: 10.1093/annonc/mdw606. Review. Erratum in: Ann Oncol. 2017 May 24;:.

33.

How will the MMR universal mass vaccination change the epidemiologic pattern of mumps? A 2012 Italian serosurvey.

Tafuri S, Gallone MS, Larocca AM, Germinario C.

Am J Infect Control. 2016 Nov 1;44(11):1420-1421. doi: 10.1016/j.ajic.2016.03.012. Epub 2016 May 2.

PMID:
27156389
34.
35.

Treatment of Newly Diagnosed Elderly Multiple Myeloma.

Fouquet G, Gay F, Boyle E, Bringhen S, Larocca A, Facon T, Leleu X, Palumbo A.

Cancer Treat Res. 2016;169:123-143. Review.

PMID:
27696261
36.

Long time immunogenicity of measles vaccine in the vaccination era: An open question.

Gallone MS, Germinario C, Larocca A, Tafuri S.

Hum Vaccin Immunother. 2017 Jan 2;13(1):117-119. doi: 10.1080/21645515.2016.1227519. Epub 2016 Sep 26.

37.

Optimizing Treatment for Elderly Patients With Newly Diagnosed Multiple Myeloma: A Personalized Approach.

Larocca A, Palumbo A.

J Clin Oncol. 2016 Oct 20;34(30):3600-3604. doi: 10.1200/JCO.2016.68.6113.

38.

Nuances in the Management of Older People With Multiple Myeloma.

Pawlyn C, Gay F, Larocca A, Roy V, Ailawadhi S.

Curr Hematol Malig Rep. 2016 Jun;11(3):241-51. doi: 10.1007/s11899-016-0323-4. Review.

39.

Monitoring the process of measles elimination by serosurveillance data: The Apulian 2012 study.

Tafuri S, Gallone MS, Gallone MF, Pappagallo MT, Larocca A, Germinario C.

Vaccine. 2016 Apr 19;34(18):2092-5. doi: 10.1016/j.vaccine.2016.03.011. Epub 2016 Mar 14.

PMID:
26988260
40.

A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myeloma.

Larocca A, Bringhen S, Petrucci MT, Oliva S, Falcone AP, Caravita T, Villani O, Benevolo G, Liberati AM, Morabito F, Montefusco V, Passera R, De Rosa L, Omedé P, Vincelli ID, Spada S, Carella AM, Ponticelli E, Derudas D, Genuardi M, Guglielmelli T, Nozzoli C, Aghemo E, De Paoli L, Conticello C, Musolino C, Offidani M, Boccadoro M, Sonneveld P, Palumbo A.

Leukemia. 2016 Jun;30(6):1320-6. doi: 10.1038/leu.2016.36. Epub 2016 Feb 22.

41.

European Myeloma Network guidelines for the management of multiple myeloma-related complications.

Terpos E, Kleber M, Engelhardt M, Zweegman S, Gay F, Kastritis E, van de Donk NW, Bruno B, Sezer O, Broijl A, Bringhen S, Beksac M, Larocca A, Hajek R, Musto P, Johnsen HE, Morabito F, Ludwig H, Cavo M, Einsele H, Sonneveld P, Dimopoulos MA, Palumbo A; European Myeloma Network.

Haematologica. 2015 Oct;100(10):1254-66. doi: 10.3324/haematol.2014.117176.

42.

How I treat fragile myeloma patients.

Larocca A, Palumbo A.

Blood. 2015 Nov 5;126(19):2179-85. doi: 10.1182/blood-2015-05-612960. Epub 2015 Aug 31. Review.

43.

Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma.

Palumbo A, Gay F, Cavallo F, Di Raimondo F, Larocca A, Hardan I, Nagler A, Petrucci MT, Hajek R, Pezzatti S, Delforge M, Patriarca F, Donato F, Cerrato C, Nozzoli C, Yu Z, Boccadifuoco L, Caravita T, Benevolo G, Guglielmelli T, Vincelli D, Jacques C, Dimopoulos MA, Ciccone G, Musto P, Corradini P, Cavo M, Boccadoro M.

J Clin Oncol. 2015 Oct 20;33(30):3459-66. doi: 10.1200/JCO.2014.60.2466. Epub 2015 Aug 17.

PMID:
26282661
44.

Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: results from a Gruppo Italiano Malattie EMatologiche dell'Adulto Multiple Myeloma Working Party study.

Musto P, Simeon V, Grossi A, Gay F, Bringhen S, Larocca A, Guariglia R, Pietrantuono G, Villani O, D'Arena G, Cuomo C, Musto C, Morabito F, Petrucci MT, Offidani M, Zamagni E, Tacchetti P, Conticello C, Milone G, Palumbo A, Cavo M, Boccadoro M.

Stem Cell Res Ther. 2015 Apr 17;6:64. doi: 10.1186/s13287-015-0033-1.

45.

Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report.

Palumbo A, Bringhen S, Mateos MV, Larocca A, Facon T, Kumar SK, Offidani M, McCarthy P, Evangelista A, Lonial S, Zweegman S, Musto P, Terpos E, Belch A, Hajek R, Ludwig H, Stewart AK, Moreau P, Anderson K, Einsele H, Durie BG, Dimopoulos MA, Landgren O, San Miguel JF, Richardson P, Sonneveld P, Rajkumar SV.

Blood. 2015 Mar 26;125(13):2068-74. doi: 10.1182/blood-2014-12-615187. Epub 2015 Jan 27. Erratum in: Blood. 2016 Mar 3;127(9):1213. Erratum in: Blood. 2016 Mar 3;127(9):1213. Blood. 2016 Aug 18;128(7):1020.

46.

A seroprevalence survey on varicella among adults in the vaccination era in Apulia (Italy).

Tafuri S, Gallone MS, Cappelli MG, Gallone MF, Larocca AM, Germinario C.

Vaccine. 2014 Nov 12;32(48):6544-7. doi: 10.1016/j.vaccine.2014.08.088. Epub 2014 Sep 16.

PMID:
25236583
47.

Gallbladder endoscopic drainage plus extracorporeal shock wave lithotripsy for Mirizzi syndrome type I complicated by acute cholecystitis.

Bassi M, Muratori R, Larocca A, Cennamo V.

Dig Liver Dis. 2014 Oct;46(10):961-2. doi: 10.1016/j.dld.2014.06.001. Epub 2014 Jul 5. No abstract available.

PMID:
25008144
48.

Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study.

Bringhen S, Petrucci MT, Larocca A, Conticello C, Rossi D, Magarotto V, Musto P, Boccadifuoco L, Offidani M, Omedé P, Gentilini F, Ciccone G, Benevolo G, Genuardi M, Montefusco V, Oliva S, Caravita T, Tacchetti P, Boccadoro M, Sonneveld P, Palumbo A.

Blood. 2014 Jul 3;124(1):63-9. doi: 10.1182/blood-2014-03-563759. Epub 2014 May 22.

49.

Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy.

Mateos MV, Bringhen S, Richardson PG, Lahuerta JJ, Larocca A, Oriol A, Boccadoro M, García-Sanz R, Di Raimondo F, Esseltine DL, van de Velde H, Desai A, Londhe A, San Miguel JF, Palumbo A.

Haematologica. 2014 Jun;99(6):1114-22. doi: 10.3324/haematol.2013.099341. Epub 2014 Apr 24.

50.

Pomalidomide for the treatment of relapsed-refractory multiple myeloma: a review of biological and clinical data.

Offidani M, Corvatta L, Caraffa P, Leoni P, Pautasso C, Larocca A, Palumbo A.

Expert Rev Anticancer Ther. 2014 May;14(5):499-510. doi: 10.1586/14737140.2014.906904. Epub 2014 Apr 17. Review.

PMID:
24738833

Supplemental Content

Loading ...
Support Center